Showing results (391-400 of 576) with videos related to
Sort By:
Pageof 58
American Journal of Hematology|June 17, 2022
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higherElias J Jabbour, Nicholas J Short, Nitin Jain, et al.Blood Advances|February 6, 2026
Prospective Feasibility Study of Peripheral Blood for MRD Detection in Acute Myeloid Leukemia by Flow CytometryShaoying Li, Nicholas J Short, Wei Wang, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 13, 2022
Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results AnalysisAmy M Berkman, Clark R Andersen, Branko Cuglievan, et al.Leukemia|May 3, 2023
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRDPhilip A Thompson, Michael J Keating, Alessandra Ferrajoli, et al.Cancer|March 18, 2025
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemiaAlexandre Bazinet, Alex Bataller, Tapan Kadia, et al.Journal of Hematology & Oncology|June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CMLKapil Saxena, Elias Jabbour, Ghayas Issa, et al.Journal of Medicinal Chemistry|January 4, 2019
Design and in Vivo Characterization of A1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba SeriesDilip K Tosh, Harsha Rao, Amelia Bitant, et al.American Journal of Hematology|February 27, 2021
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabineKiyomi Morita, Nitin Jain, Hagop Kantarjian, et al.Clinical Lymphoma, Myeloma & Leukemia|February 10, 2020
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic LeukemiaGuillaume Richard-Carpentier, Elias Jabbour, Nicholas J Short, et al.Blood|October 25, 2023
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remissionElias Jabbour, Fadi G Haddad, Nicholas J Short, et al.Pageof 58